Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
US FDA approval based on NEURO-TTRansform Phase III results
Subscribe To Our Newsletter & Stay Updated
